Fig. 7From: Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironmentCB-1158 combines with gemcitabine to inhibit tumor growth. a CB-1158 in combination with gemcitabine treatment in the CT26 model (left), the LLC model (center), or the 4T1 model (right) inhibited tumor growth. N = 10 per group. b On study day 14, CT26 tumors from animals treated with CB-1158 and gemcitabine had decreased myeloid cells (upper left), increased NK cells (upper right), decreased suppressive macrophages (lower left), and increased inflammatory macrophages (lower right) as determined by flow cytometry compared to vehicle-treated animalsBack to article page